Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines
Cui-rong Zhao1, Rui-qi Wang, Gang Li
1Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Wen Hua Xi Rd, Jinan 250012, China.
Abstract:
New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 5l and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituent on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity.
Insights
New indazole-based diarylureas show potent anticancer activity, outperforming sorafenib against various cancer cell lines. Specific derivatives with trifluoromethyl or halogen substituents exhibit enhanced efficacy and lower toxicity.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Diarylureas represent a significant class of compounds with demonstrated anticancer properties.
- Sorafenib, a multi-kinase inhibitor, serves as a benchmark for anticancer drug efficacy.
- Exploring novel chemical scaffolds is crucial for developing more effective cancer therapeutics.
Purpose of the Study:
- To synthesize and evaluate a new series of indazole-based diarylurea derivatives for their anticancer potential.
- To compare the efficacy of these novel compounds against a panel of human cancer cell lines with the established drug sorafenib.
- To investigate the structure-activity relationships, particularly the influence of substituents on the indazole ring.
Main Methods:
- Synthesis of a novel series of indazole-based diarylurea compounds.
- In vitro anticancer activity screening against a diverse panel of human cancer cell lines (H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901, MDA-MB-231).
- Acute toxicity assessment of select compounds and comparison with sorafenib.
Main Results:
- Most synthesized indazole-based diarylureas demonstrated superior or comparable anticancer activity to sorafenib across multiple cell lines.
- Derivatives featuring trifluoromethyl or halogen substituents on the indazole ring exhibited enhanced potency.
- Compounds 5a, 5b, and 5i showed reduced acute toxicity compared to sorafenib, with compound 5i displaying the most significant anticancer effects.
Conclusions:
- Indazole-based diarylureas represent a promising class of anticancer agents.
- Strategic substitution on the indazole core, particularly with trifluoromethyl groups, can significantly enhance anticancer potency and potentially improve safety profiles.
- Compound 5i is identified as a lead candidate for further development due to its potent anticancer activity and favorable toxicity profile.
Related Concept Videos
Inhibition of Cdk Activity
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Oral Hypoglycemic Agents: Sulfonylureas
Inhibitors of Bacterial DNA Synthesis

